Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Lowered by StockNews.com

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

AGIO has been the topic of a number of other reports. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 17th. Royal Bank of Canada raised their price target on Agios Pharmaceuticals from $44.00 to $53.00 and gave the company an “outperform” rating in a research report on Tuesday, June 4th. Finally, The Goldman Sachs Group upped their price objective on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a report on Tuesday, June 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $50.67.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $42.05 on Wednesday. The company’s 50 day simple moving average is $38.72 and its two-hundred day simple moving average is $30.98. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $49.06. The stock has a market capitalization of $2.39 billion, a PE ratio of -6.65 and a beta of 0.78.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, topping the consensus estimate of ($1.65) by $0.20. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The business had revenue of $8.19 million during the quarter, compared to analysts’ expectations of $8.37 million. During the same period in the previous year, the business earned ($1.47) earnings per share. The firm’s revenue was up 46.0% on a year-over-year basis. On average, research analysts anticipate that Agios Pharmaceuticals will post -2.68 EPS for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,791 shares of Agios Pharmaceuticals stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total value of $214,642.05. Following the transaction, the director now owns 137,396 shares in the company, valued at $3,785,259.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Farallon Capital Management LLC boosted its position in Agios Pharmaceuticals by 34.1% during the 1st quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock valued at $163,469,000 after buying an additional 1,423,000 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Agios Pharmaceuticals by 800.5% during the first quarter. Assenagon Asset Management S.A. now owns 454,801 shares of the biopharmaceutical company’s stock worth $13,298,000 after purchasing an additional 404,297 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after purchasing an additional 388,381 shares during the last quarter. Norges Bank purchased a new position in Agios Pharmaceuticals during the 4th quarter valued at about $6,826,000. Finally, Frazier Life Sciences Management L.P. raised its position in Agios Pharmaceuticals by 79.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 523,166 shares of the biopharmaceutical company’s stock valued at $11,651,000 after purchasing an additional 231,164 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.